Novartis India Acquires Pfizer's Minipress Trademarks for Rs 1,250 Crore
Novartis India has approved the acquisition of Pfizer's Minipress and Minipres trademarks in India for approximately Rs 1,250 crore, including related intellectual property rights. Minipress XL, containing prazosin, is used to treat hypertension and urinary symptoms of benign prostatic hyperplasia, generating Rs 228.6 crore in revenue with a 6.3% CAGR over four years. Pfizer will discontinue marketing and sales of Minipress XL in India following Pfizer Inc USA's decision to cease its manufacture, with the transaction completed through asset purchase and trademark assignment agreements.
First-hand measurement across 2 sources
We measured how 2 outlets covered this story. No outlet gave this story a measurable political slant — there is no left–right reading to report. Overall sentiment is neutral (51/100). Lens Score 42/100.
Outlets measured: news18, freepressjournal. See how each one headlined and framed the same story in the source comparison below.
AI Analysis
Sentiment was consistent across outlets (50–52/100), indicating broadly factual reporting rather than editorialising.
Coverage timeline
freepressjournal broke this story on 7 Sept, 07:06 am. Other outlets followed.